

9^a edizione

Progetto **CANOA**

CARCINOMA MAMMARIO:

QUALI NOVITA' PER IL 2019?

"Saper leggere" uno studio clinico per migliorare la pratica clinica

Coordinatori scientifici:
Stefania Gori
Giovanni L. Pappagallo

PROGRAMMA

Ospedaletto di Pescantina (VR) 22/23 Marzo 2019
Villa Quaranta Park Hotel

GRUPPO A

QUESITO CLINICO:

Nelle pazienti in postmenopausa con carcinoma mammario metastatico HR-positivo/HER2-negativo e mutazione PIK3CA, in ripresa (progressione) di malattia durante o dopo terapia con antiaromatasi, è opportuno considerare l'aggiunta di Alpelisib a Fulvestrant?

SINTESI DELLE EVIDENZE E PROBLEMATICHE

Jennifer Foglietta

P.O. Narni-Amelia (TR)

QUESITO GRUPPO A:

P: pazienti con carcinoma mammario metastatico HR+/HER2- e mutazione PIK3CA in progressione durante/dopo inibitore dell'aromatasi

I: fulvestrant+ alpelisib

C: fulvestrant

O: PFS, OS, safety (iperglicemia, rash e diarrea)

ALPELISIB + FULVESTRANT FOR HR+, HER2- ADVANCED BREAST CANCER: RESULTS OF THE PHASE III SOLAR-1 TRIAL

ESMO 2018

Fabrice André,¹ Eva Maria Ciruelos,² Gabor Rubovszky,³ Mario Campone,⁴ Sibylle Loibl,⁵ Hope S Rugo,⁶ Hiroji Iwata,⁷ Pierfranco Conte,⁸ Ingrid A Mayer,⁹ Bella Kaufman,¹⁰ Toshinari Yamashita,¹¹ Yen-Shen Lu,¹² Kenichi Inoue,¹³ Masato Takahashi,¹⁴ Zsuzsanna Pápai,¹⁵ Anne-Sophie Longin,¹⁶ David Mills,¹⁷ Celine Wilke,¹⁷ Samit Hirawat,¹⁸ Dejan Juric¹⁹

¹Gustave Roussy, INSERM U981, Université Paris-Sud, Villejuif, France; ²Hospital Universitario 12 de Octubre, Madrid, Spain; ³National Institute of Oncology, Budapest, Hungary; ⁴Institut de Cancérologie de l'Ouest, St Herblain, France; ⁵German Breast Group, Neu-Isenburg, Germany and Centre for Haematology and Oncology Bethanien, Frankfurt, Germany; ⁶UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; ⁷Aichi Cancer Center, Nagoya, Japan; ⁸Istituto Oncologico Veneto, Padua, Italy and Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy; ⁹Vanderbilt University, Nashville, TN, USA; ¹⁰Chaim Sheba Medical Center, Tel Hashomer, Israel; ¹¹Kanagawa Cancer Center, Yokohama, Japan; ¹²National Taiwan University Hospital, Taipei, Taiwan; ¹³Saitama Cancer Center, Saitama, Japan; ¹⁴NHO Hokkaido Cancer Center, Sapporo, Japan; ¹⁵Duna Medical Center, Budapest, Hungary; ¹⁶Novartis Pharma S.A.S, Paris, France; ¹⁷Novartis Pharma AG, Basel, Switzerland; ¹⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ¹⁹Massachusetts General Hospital, Boston, MA, USA


LBA3

Alpelisib (ALP) + Fulvestrant (FUL) for Advanced Breast Cancer (ABC): Phase 3 SOLAR-1 Trial Results

SABCS 2018

Dejan Juric,^{1*} Eva Maria Ciruelos,² Gabor Rubovszky,³ Mario Campone,⁴ Sibylle Loibl,⁵ Hope S. Rugo,⁶ Hiroji Iwata,⁷ Pierfranco Conte,⁸ Ingrid A. Mayer,⁹ Bella Kaufman,¹⁰ Toshinari Yamashita,¹¹ Yen-Shen Lu,¹² Kenichi Inoue,¹³ Masato Takahashi,¹⁴ Zsuzsanna Pápai,¹⁵ Anne-Sophie Longin,¹⁶ David Mills,¹⁷ Celine Wilke,¹⁷ Michelle Miller,¹⁸ Naveen Babbar,¹⁸ Fabrice André¹⁹

SOLAR-1: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial (NCT02437318)¹



- The primary endpoint included all randomized patients in the *PIK3CA*-mutant cohort; PFS was analyzed in the *PIK3CA*-non-mutant cohort as a proof of concept
- Safety was analyzed for all patients who received ≥ 1 dose of study treatment, in both cohorts

ABC, advanced breast cancer; AI, aromatase inhibitor; ALP, alpelisib; CBR, clinical benefit rate; ctDNA, circulating tumor DNA; ECOG, Eastern Cooperative Oncology Group; FUL, fulvestrant; HER2-, human epidermal growth factor receptor-2-negative; IM, intramuscular; ORR, overall response rate; OS, overall survival; PBO, placebo; PFS, progression-free survival; PO, oral; QD, once daily; R, randomization.

^a More than 90% of patients had mutational status identified from archival tissue.

^b Fulvestrant given on Day 1 and Day 15 of the first 28-day cycle, then Day 1 of subsequent 28-day cycles.

1. Andre F, et al. ESMO 2018. Abstract LBA3 [oral].

This presentation is the intellectual property of Dejan Juric. Contact Juric.Dejan@mgh.harvard.edu for permission to reprint and/or distribute.



Cit. Gigi Pappagallo

Clinical Cancer Research

[Advanced Search](#)[Home](#)[About](#)[Articles](#)[For Authors](#)[Alerts](#)[News](#)

Research Article

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle, Sibel Blau, Jose Alejandro Perez Fidalgo, Michael Gnant, Peter A. Fasching, Marco Colleoni, Antonio C. Wolff, Eric P Winer, Christian F. Singer, Sara A. Hurvitz, Laura Garcia Estevez, Peter A. van Dam, Sherko Kümmel, Christoph Mundhenke, Frankie A Holmes, Naveen Babbar, Laure Charbonnier, Ivan Diaz-Padilla, Florian D. Vogl, Dalila Sellami, and Carlos L. Arteaga

DOI: 10.1158/1078-0432.CCR-18-3160

VALUTAZIONE DI AFFIDABILITA'

RISCHIO DI BIAS

ANALISI DI SOTTOGRUPPO

IMPRECISIONE DELLE STIME

VALUTAZIONE DI TRASFERIBILITA'

ADERENZA AL QUESITO CLINICO

VALUTAZIONE DI RILEVANZA

ADEGUATEZZA DEL RISULTATO

VALUTAZIONE DI AFFIDABILITA'

RISCHIO DI BIAS

	OS*	ORR	PFS *	SAFETY (iperglicemia)	SAFETY-2 (rash)	SAFETY-3 (diarrea)
		Green		Green	Green	Green
PERFORMANCE		Green		Green	Green	Green
		Green		Green	Green	Green
DETECTION		Green		Green	Red	Red
		Green		Green	Green	Green

* Dati non disponibili

VALUTAZIONE DI AFFIDABILITA'


IMPRECISIONE DELLE STIME: ORR

IMPRECISO




VALUTAZIONE DI AFFIDABILITA'

IMPRECISIONE DELLE STIME: Safety (iperglicemia $g. \geq 3$)



VALUTAZIONE DI AFFIDABILITA'

IMPRECISIONE DELLE STIME: Safety (diarrea all g)



VALUTAZIONE DI AFFIDABILITA'

	OS	PFS	ORR	SAFETY-1 iperglicemia	SAFETY-2 rash	SAFETY-3 diarrea
			*	*	*	*
CERTAINTY			Bassa	Bassa	Molto bassa	bassa

* popolazione, intervento e confronto